Thank you for Subscribing to Med Tech Business Review Weekly Brief
MedTech Business Review proudly presents the Top 10 Chief Commercial Officers - 2026, recognizing leaders who are advancing commercial performance through strategic planning and market-focused leadership. These professionals oversee commercial strategies that align customer engagement, market opportunities, and growth initiatives with business objectives while responding to evolving healthcare needs. Their leadership helps organizations strengthen market positioning and expand commercial opportunities, enabling medtech companies to drive sustainable growth while supporting long-term business performance.
Top 10 Chief Commercial Officers - 2026
Chief Commercial Officer, Foundation Medicine
Troy Schurr is a commercial oncology leader with nearly 30 years of experience across the diagnostics, pharmaceutical and biotech industries. He leads commercial strategies that strengthen partnerships and advance precision medicine through next-generation sequencing solutions.
Chief Commercial Officer, Merit Medical Systems
C. Adam Smith serves as Chief Commercial Officer at Merit Medical Systems, heading the company's global commercial organization. Since joining Merit in 2018, he has held leadership roles, including international markets, marketing, franchises and regional operations, before becoming the CCO in 2025. His career reflects a focus on connecting commercial strategy with local market execution.
Chief Commercial Officer, Fulgent Genetics
At Fulgent Genetics, Brandon Perthuis serves as Chief Commercial Officer, with a focus on genetic testing and precision medicine. His work also includes oncology programs involving whole-genome sequencing and cancer therapeutics.
Chief Commercial Officer (CCO), 10x Genomics [NASDAQ: TXG]
Bringing more than 20 years in life science tools, Mennah Moustafa is Chief Commercial Officer at 10x Genomics. Her leadership experience includes 10x Genomics, Abcam, Science Exchange and Sigma-Aldrich, with a focus on commercial strategy and partnerships.
Chief Commercial Officer, Myriad Genetics [NASDAQ: MYGN]
With experience spanning diagnostics, genomics, digital health, software and subscription services, Brian Donnelly is Chief Commercial Officer at Myriad Genetics. His career includes leadership roles at Ancestry, Amazon, Illumina and GSK.
Chief Commercial Officer, Organogenesis
A regenerative medicine commercial executive, Brian H. Grow serves as Chief Commercial Officer at Organogenesis, which focuses on advanced wound care and surgical biologics. His experience spans regenerative medicine, tissue engineering and chronic wound care.
Chief Commercial Officer (CCO), Solventum
At Solventum, Heather Knight serves as Chief Commercial Officer, overseeing commercial and R&D operations across MedSurg, Dental Solutions and Health Information Systems. Her MedTech career includes senior leadership roles at Baxter, Medtronic and Covidien.
Chief Commercial Officer (CCO), Beam Therapeutics
As Chief Commercial Officer at Beam Therapeutics, John Lo focuses on commercial strategy for gene therapy programs, including treatments under development for sickle cell disease and alpha-1 antitrypsin deficiency.
Chief Commercial Officer (CCO), Mimedx Group
At MIMEDX, Kim Moller serves as Chief Commercial Officer, bringing more than 25 years of healthcare sales experience, including leadership roles with 3M, Acelity and KCI.
Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies
Leading commercial efforts in immune medicine, Sharon Benzeno, PhD focuses on T-cell therapies, precision immunology, oncology and partnerships supporting immune-based therapeutic development at Adaptive Biotechnologies.
